The Infectious Disease & Global Medicine research team takes the “standard” out of care by introducing potentially more efficient and effective ways to address every patient’s needs. By utilizing investigatory products and devices to treat infectious diseases, our team is able to take a more innovative, patient-centered approach that focuses on providing all available treatment options for the management of their condition.
OUR Clinical Trials
Clostridium difficile colitis results from disruption of normal healthy bacteria in the colon, often from antibiotics. C. difficile can also be transmitted from person to person by spores. It can cause severe damage to the colon and even be fatal.
A bloodstream infection (BSI) is defined as one or more positive blood cultures associated with systemic signs of infection such as fevers, chills, and/or hypotension. BSIs can be divided into primary and secondary. Primary BSIs occur without another defined nidus of infection. Secondary BSIs develop from a detectable area of infection as the source of the bacteremia.
New methods to treat bacterial infections without using antibiotics – monoclonal antibodies, bacteriophages. Since we are running out of effective antibiotics, there is a pressing need for these studies.
A rapidly changing virus introduced by the SARS-COV-2 in late 2020. Infected patients may experience mild to severe respiratory illness and treatments are continuing to be investigated.
Rabies is a fatal but preventable viral disease. It can spread to people and pets if they are bitten or scratched by a rabid animal. In the United States, rabies is mostly found in wild animals like bats, raccoons, skunks, and foxes.